Previous close | 64.67 |
Open | 64.54 |
Bid | 63.33 x 200 |
Ask | 63.48 x 200 |
Day's range | 61.64 - 65.75 |
52-week range | 8.28 - 99.41 |
Volume | |
Avg. volume | 6,501,153 |
Market cap | 6.99B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.91 |
Earnings date | 24 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 113.80 |
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.